FDA's Safety Review of Abortion Pill Mifepristone to Continue into Next Year

The Food and Drug Administration (FDA) announced that its ongoing safety review of mifepristone, the primary abortion pill used in the U.S., will extend into next year. The agency provided a court-ordered update, indicating that a safety study is expected to be completed by mid-December 2026, with a report on findings due no later than March 2027. The FDA will then decide on potential new restrictions or changes to the drug's use.